The T1 gene gives rise to two transcripts encoding a 62 kDa membrane-bound and a 37 kDa secreted protein with similarity to the type I IL-1 receptor. It is weakly expressed in proliferating but not in resting ®broblasts and is strongly induced during the entry of quiescent cells into the cell cycle. Here we show that the T1 gene is also transcriptionally activated in response to the treatment of ®broblasts with cycloheximide and anisomycin. These protein synthesis inhibitors are known to stimulate the JNK and p38/RK signal transduction pathways. We provide evidence that anisomycin triggers T1 gene induction through the stimulation of the p38/RK MAP kinase. This observation is in line with our ®nding that physiological activators of the p38/RK pathway, the proin¯ammatory cytokines IL-1 and TNFa, stimulate T1 gene expression eciently. Growth factor mediated T1 gene induction is a delayed early event, requiring ongoing protein synthesis. In contrast, anisomycin induces T1 gene expression at concentrations which block translation completely. Thus, transcriptional induction of the T1 gene via the p38/RK pathway is an immediate early event not requiring de novo protein synthesis. The T1 gene is strongly induced by various mitogens in quiescent NIH3T3 ®broblasts but not in ras transformed NIH3T3 cells. In contrast, all of the three tested agent which activate the p38/RK pathway, IL-1, TNFa, and anisomycin led to strong T1 gene expression in normal and ras transformed NIH3T3 cells alike. Thus, the T1 gene can be induced through the activation of at least two MAP kinase pathways: signaling through the ERK pathway can occcur in normal but not in ras transformed NIH3T3 cells, whereas the signaling through the p38/RK pathway is not aected by ras transformation.
Introduction
T1, also known as ST2 and DER4, was identi®ed as a gene activated by growth factors and the induced expression of the Ha-ras or v-mos oncogenes in murine ®broblasts Tominaga, 1989; Werenskiold et al., 1989; Lanahan et al., 1992) . Later, the human and rat homolog have been isolated Bergers et al., 1994) .
T1 is transcribed into two mRNA species of 2.7 kb and 5 kb which arise from alternative 3' processing . The 5 kb T1 transcript is found in mast cells (GaÈ chter et al., 1996) , in subpopulations of cells in hematopoietic organs (embryonic liver, spleen, bone marrow) (RoÈ ûler et al., 1995) and the lung (Bergers et al., 1994) throughout ontogenesis. It encodes a 567 amino acid transmembrane protein (T1M) which belongs to the interleukin 1 receptor (IL-IR) family Mitcham et al., 1996; Parnet et al., 1996) . The amino acid sequences of the ectodomain of T1 and the type I IL-1R are 28% identical and the intracellular portions share 40% identity. The genes encoding the two IL-1 receptors and T1 are tightly linked on mouse chromosome 1 (Tominaga et al., 1991) and human chromosome 2 (band 2q 12 ± 13) (Sims et al., 1995) . In addition, the intron/exon structures of the type I IL-1R and the T1 gene are conserved, suggesting a common ancestor (Sims et al., 1995) . T1M does not bind any of the IL-1R ligands IL-1a, IL-1b, or IL-1ra (RoÈ ûler et al., 1993; Danescu and Werenskiold, 1995; Kumar et al., 1995; Gayle et al., 1996) . However, there is indirect evidence that it stimulates similar or identical signal transduction cascades as the IL-1R. Both, the type I IL-1R and a chimeric protein consisting of the extracellular domain of the IL-1R and the intracellular domain of T1M are able to activate NFkB, the MAP kinase p38/ RK, and transcription from the IL-8 promoter upon IL-1a or IL-1b stimulation (Kumar et al., 1995; Reikerstorfer et al., 1995; Mitcham et al., 1996) .
Recently, a 227 amino acid membrane bound putative T1 ligand was cloned from human and mouse . Two additional soluble putative T1 ligands were partly puri®ed and characterized as proteins of 32 kDa and 18 kDa (Kumar et al., 1995) . While the membrane bound putative ligand was unable to activate NFkB and transcription from the IL-8 promoter upon binding to T1M , protein fractions containing the 32 kDa and 18 kDa putative soluble ligands were able to activate the p38/RK MAP kinase via T1M (Kumar et al., 1995) .
The 2.7 kb T1 transcript was found in ®broblasts, the embryonic skin, in the retina and bones (RoÈ ûler et al., 1995) , in developing mammary glands 3 ± 4 weeks after birth as well as in experimental Ha-ras induced mammary tumors (RoÈ ûler et al., 1993) . It encodes a 327 amino acid protein (T1S) which is N-glycosylated and secreted Tominaga, 1989; Werenskiold, 1992; Takagi et al., 1993; Kalousek et al., 1994) . Apart from nine amino acids at its carboxy terminus, T1S is identical to the extracellular domain of T1M . Soluble forms of type II IL-1R (Symons et al., 1995) as well as the related vaccinia virus B15R protein (Alcami and Smith, 1992; Spriggs et al., 1992) have previously been described and postulated to function as type I IL-1R antagonists.
Serum responsive genes have been divided intò immediate early' and`delayed early' genes based on the kinetics of their induction and the dependence on ongoing protein synthesis, the former being independent and the latter dependent on translation (Lau and Nathans, 1991) . T1 mRNA accumulates in response to serum with a kinetics typical for delayed early gene transcripts peaking around 6 ± 10 h after serum stimulation (Tominaga, 1989; Werenskiold et al., 1989) . Delayed early genes are thought to be the targets of immediate early transcription factors. Indeed, we and others have demonstrated that the T1 gene and its rat homologue ®t-1 are induced in response to the expression of the immediate early serum response protein c-Fos and FosB (Bergers et al., 1994; Kalousek et al., 1994) . Thus, it can be assumed that T1 gene induction in response to the mitogenic stimulation of quiescent cells is the consequence of cfos gene activation. Similarly, the onset of ras oncogene expression, as it is arti®cially achieved in conditional expression systems, is followed by the transient accumulation of c-Fos which in turn triggers the activation of the T1 gene. However, sustained expression of oncogenic ras results in the downregulation of the c-fos and consequently of the T1 gene (submitted for publication). This repression occurs in spite of permanent activation of the MAP kinases ERK-1 and ERK-2 and is the consequence of elevated AP-1 activity (unpublished observation).
The classi®cation of the T1 gene as an immediate-or delayed early serum responsive gene based on its serum inducibility in the presence of the protein synthesis inhibitor cycloheximide has been controversial. Three groups have described T1 and ®t-1 as delayed early genes based on the observation that the protein synthesis inhibitor cycloheximide blocked serum inducibility in Swiss 3T3 , Balb/c 3T3 (Lanahan et al., 1992) and rat-1A cells (Bergers et al., 1994) . In contrast, Yanagisawa et al., 1992 classi®ed T1 as an immediate early gene since cycloheximide in their experiments did not abolish the serum induction of T1 in Balb/c 3T3 cells.
In this study we demonstrate that the T1 gene is eciently induced by the translation inhibitors cycloheximide and anisomycin in NIH3T3 but not in Swiss 3T3 cells. The substance SB203580 , an inhibitor of the MAP kinases p38/RK and certain isoforms of JNK (Whitmarsh et al., 1997) blocked anisomycin mediated T1 gene expression completely. This ®nding and the observation that u.v. does not result in T1 gene induction suggest that p38/ RK is involved in the transmission of the anisomycin triggered signal to activate the T1 gene.
The MAP kinase p38/RK (also known as CSBP and Mpk2) (Freshney et al., 1994; Lee et al., 1994; Rouse et al., 1994) is activated in mammalian cells in response to IL-1, TNFa, and lipopolysaccaride and by stress signals (Han et al., 1994; Rouse et al., 1994; Cuenda et al., 1995; Beyaert et al., 1996) . Its activator is the dual speci®city kinase MKK6 (Raingeaud et al., 1996) which phosphorylates p38/RK at both threonine and tyrosine residues . Once activated, it phosphorylates and thereby activates MAPKAP kinase-2 (Freshney et al., 1994; Rouse et al., 1994; Cuenda et al., 1995; Beyaert et al., 1996) and MAPKAP kinase-3 (Ludwig et al., 1996; McLaughlin et al., 1996) which in turn catalize the phosphorylation of the small heat shock protein Hsp25 (Freshney et al., 1994; Rouse et al., 1994; Cuenda et al., 1995; Beyaert et al., 1996; Ludwig et al., 1996; McLaughlin et al., 1996) . p38/RK has been shown to phosphorylate the transcription factors ATF-2 (DeÂ rijard et al., 1995; Raingeaud et al., , 1996 , Elk-1 (Cano et al., 1995; Zinck et al., 1995; Raingeaud et al., 1996) , and Max (Zervos et al., 1995) in vitro, however the in vivo activation of these transcription factors by p38/RK has not yet been demonstrated. Here we show that anisomycin treatment resulted in the transcriptional activation of the T1 gene. This response was observed using anisomycin concentrations which do not block translation as well as high concentrations which inhibit protein synthesis completely. Hence, the T1 gene responds in an immediate early mode to the p38/RK signal transduction cascade stimulated by anisomycin while previous studies have shown that mitogenic stimuli, signaling through the MAP kinases of the ERK family, stimulate the T1 gene in a delayed early manner. We further demonstrate that two physiological activators of the p38/RK pathway, IL-1 and TNFa also eciently trigger T1 gene induction.
Serum and growth factor triggered T1 gene induction is abrogated in ras transformed NIH3T3 cells. However, anisomycin, IL-1, and TNFa mediated T1 gene induction is not aected by the expression of the ras oncogene. p38/RK is not phosphorylated in unstimulated ras transformed NIH3T3 cells while the MAP kinases ERK-1 and ERK-2 are permanently in the phosphorylated, activated state. Thus, while the expression of a ras oncogene leads to the sustained activation of the ERK pathway and presumably through some feedback mechanism to T1 gene downregulation, it does not aect the p38/RK pathway and does not interfere with anisomycin, IL-1, and TNFa mediated T1 gene induction.
Results
Two dierent pathways are used for the induction of T1 by serum and cycloheximide/anisomysin
We have previously reported that serum growth factors fail to induce the T1 gene in Swiss 3T3 ®broblasts if protein synthesis was blocked by the treatment of the cells with cycloheximide . However, we later observed that cycloheximide did not prevent T1 mRNA accumulation in NIH3T3 cells, another murine ®broblastic cell line (Figure 1a ). On ®rst view this is in contradiction to our previous claim that T1 is a delayed early serum responsive gene. However, cycloheximide is known to have pleiotropic eects; besides binding to ribosomes and thereby blocking translation it can also activate the JNK pathway (Kyriakis et al., 1994) . Other protein synthesis inhibitors such as puromycin and emetine do not share this property with cycloheximide (Cano et al., 1994; Kyriakis et al., 1994) and were used to test whether serum growth factor mediated T1 gene expression in NIH3T3 cells is also dependent on ongoing protein synthesis. As can be seen in Figure 1b , serum stimulation in the presence of either puromycin or emetine did not result in the accumulation of T1 mRNA indicating that T1 is indeed a delayed early serum responsive gene.
These ®ndings suggest that cycloheximide treatment is sucient to promote the accumulation of T1 mRNA. Indeed, the addition of cycloheximide to NIH3T3 cells resulted in the synthesis of T1 mRNA (Figure 1c) . However, no T1 mRNA accumulated under the same conditions in Swiss 3T3 cells which is in accordance with our previous ®nding . Anisomycin is another protein synthesis inhibitor which shares with cycloheximide the property of stimulating signal transduction pathways thereby triggering the expression of susceptible genes (Almendral et al., 1988; Quantin and Breathnach, 1988; Mahadevan and Edwards, 1991; Liang et al., 1996) . Anisomycin treatment resulted in the accumulation of even higher levels of T1 mRNA in all ®broblastic cell lines tested. In contrast to serum growth factors which induced the T1 gene with similar eciency in the dierent, non-transformed ®broblastic cell lines tested (Figure 1c ), anisomycin treatment led to very high, intermediate and low levels of T1 mRNA accumulation in NIH3T3, Balb/c 3T3 and Swiss 3T3 cells, respectively.
We have previously observed that serum-mediated T1 gene induction is attenuated in NIH3T3 cell lines which express the Ha-ras oncogene such as the NFR-2 cell line used in this study (Figure 1c ). In contrast, we found that cycloheximide and anisomycin treatment led to similar levels of T1 mRNA accumulation in normal and ras-transformed NIH3T3 cells (Figure 1c ). This is a further indication that growth factors and cycloheximide/anisomycin operate through dierent signal transduction pathways.
Anisomycin inducibility is not a general phenomenon among delayed early serum responsive genes
We tested whether anisomycin treatment aects two other well studied delayed early serum responsive genes. For this experiment we used Balb/c 3T3 cells because the delayed early serum responsive genes encoding stromelysin and interstial collagenase are well induced by EGF, serum, and TPA in these but not in NIH3T3 cells. Balb/c 3T3 cells were rendered quiescent by serum deprivation and subsequently stimulated with EGF, serum, TPA and anisomycin. Serum-and TPA stimulation led to the well documented induction of the three tested delayed early serum responsive genes (reviewed in . In contrast, anisomycin treatment resulted only in T1 mRNA accumulation but did not stimulate stromelysin and collagenase gene transcription (Figure 2 ). This shows that the observed pattern of gene induction by mitogens and anisomycin is overlapping but not congruent. and Swiss 3T3 cells were stimulated with 10% FCS in the presence or absence of 10 mg/ml puromycin or 10 mg/ml emetine for 6 h. (c) Proliferating and serum starved NIH3T3, NFR-2, Swiss 3T3, and Balb/c 3T3 cells were treated with protein synthesis inhibitors (cycloheximide, 50 mg/ml; anisomycin, 1 mg/ml) or 10% FCS, respectively. RNA was collected after the time periods (h) indicated above the lanes and 5 mg of total RNA was subjected to Northern blot analysis using T1 cDNA as the probe stomelysin collagenase T1 -EGF serum TPA aniso Figure 2 Anisomycin does not induce the delayed early serum responsive genes encoding stromelysin and interstitial collagenase. Serum starved Balb/c 3T3 cells were treated with 35 ng/ml epidermal growth factor (EGF), 10% FCS, 200 ng/ml 12-Otetradecanoylphorbol-13-acetate (TPA), or 1 mg/ml anisomycin (aniso) for 6 h. Three identical Northern blots were prepared and hybridized with radioactive labeled probes recognizing stromelysin, collagenase and T1 mRNA T1 is transcriptionally induced by anisomycin Dierent mechanisms can be envisaged for anisomycin mediated T1 mRNA accumulation. Anisomycin aects cellular physiology in two ways. By virtue of binding to ribosomes it can block translation and by an unknown mechanism it can stimulate MAP kinase pathways. The two modes of operation exhibit dierent dose dependencies and can thus be distinguished. While protein synthesis is only inhibited at anisomycin concentrations above 40 ng/ml ( Figure 3b ) it turns on signal transduction pathways at lower concentrations (Mahadevan and Edwards, 1991) . As can be seen in Figure 3a , anisomycin led to the signi®cant accumulation of the 2.7 kb T1 mRNA at concentrations which are insucient to block protein synthesis and the maximal level of T1 mRNA was reached at a concentration of 100 ng/ml which still allowed translation to proceed at ca. 40% of its eciency in the absence of the drug.
Another mRNA which we fortuitously found to accumulate in response to anisomycin treatment of NIH3T3 cells encodes mouse tissue factor ( Figure 3c ). However, this response is only observed at anisomycin concentrations which are suciently high to block protein synthesis completely, i.e. approximately 30 times higher than the concentrations needed to achieve accumulation of T1 mRNA. We assume that the accumulation of tissue factor mRNA is the result of mRNA stabilization possibly due to the lack of the synthesis of a labile RNase.
This result suggests that transcriptional activation of the T1 gene is the cause of or contributes to anisomycin-mediated T1 mRNA accumulation. In order to test whether anisomycin does indeed trigger T1 gene transcription we performed nuclear run on assays. Nuclei were isolated from NIH3T3 cells which were serum starved for 1 day and exposed to serum or anisomycin for 2 and 3.5 h, respectively. Radioactively labeled run on RNA was prepared and hybridized to Southern blots containing genomic and complementary T1 DNA (Figure 4 ). All DNA fragments containing transcribed portions of the T1 gene hybridized to runon RNAs from anisomycin and serum stimulated but not from unstimulated cells. One genomic DNA fragment contains repetitive DNA. It scores positive in this hybridization experiment with all three dierent run-on probes and serves as an internal control for equal quality of the nuclear run-on transcripts and the DNA transfer. We conclude from this experiment that anisomycin treatment leads to T1 gene expression and that the extent of transcription in response to serum and anisomycin is similar.
Using run on transcription assays we could show that anisomycin was also able to induce T1 transcription in the ras transformed cell line NFR-2 (data not shown).
A T1 reporter gene construct can be induced by ansiomycin
Based on the ®nding that anisomycin stimulation leads to the transcriptional activation of the T1 gene we investigated whether a T1 reporter gene construct can be stimulated similarly. A plasmid (pFH6) was constructed which contains a CAT gene¯anked by 7.4 kb and 5 kb of the T1 gene 5' and 3'¯anking regions, respectively. It includes the ®rst and part of the second as well as part of the eighth exon and was stably introduced into NIH3T3 cells ( Figure 5 ). Since S-methionine for 1 h. TCA precipitable radioactivity was measured and the values corrected for total protein content. The value obtained for the cell culture which received no anisomycin was set to 100%. (c) NIH3T3 cells were treated with anisomycin at the concentrations indicated above the lanes and RNA was isolated 6 h later. 5 mg of total RNA was subjected to Northern blot analysis using a mouse tissue factor and a T1 cDNA probe anisomycin blocks translation the cell clones could not be scored for CAT activity in response to anisomycin stimulation. Therefore we prepared total RNA of two transfected cell clones which were rendered quiescent by serum starvation and were either stimulated with serum or anisomycin for 4 and 8 h. The RNA was subjected to Northern blot analysis using a CAT speci®c DNA probe ( Figure 5 ). The same Northern blot was reprobed with a T1 cDNA probe in order to monitor the induction of the endogenous T1 gene. We found very ecient expression of the transfected gene in response to serum and anisomycin stimulation. The amount of CAT mRNA which accumulated in anisomycin treated cells was higher than in mitogenically stimulated cells. The ratio of accumulated CAT mRNA under the two conditions is similar to that of the endogenous T1 gene.
The inhibitor of the MAP kinase p38/RK and some JNK isoforms, SB203580, interferes with anisomycin-mediated T1 gene induction
The p38/RK MAP kinase was recently shown to be essential for anisomycin induced glucose uptake into KB cells (Gould et al., 1995) . This observation motivated us to test whether the p38/RK pathway is also involved in anisomycin-mediated T1 gene induc- .4, were rendered quiescent by serum starvation for 24 h. Fresh medium containing 10% FCS or anisomycin at a ®nal concentration of 100 ng/ml was added and RNA collected after 4 and 8 h. The RNA was subjected to Northern blot analysis using in succession a CAT and a T1 speci®c probe to detect the exogenous and endogenous T1 transcripts, respectively. In the lower part of the ®gure the genomic organization of the T1 gene (upper part) and the pFH6 construct (lower part) are shown. pFH6 contains 7.4 kb and 5 kb of the 5' and 3' regions of the T1 gene, respectively, including exon 1 and part of the exons 2 and 8. The identi®cation and characterization of the enhancer element has been described earlier (TruÈ b et al., 1994) . Relevant cloning sites, the translational initiation and stop codons and the transcriptional start site which is used in ®broblasts are indicated. Filled and striped boxes represent non coding and coding regions of the T1 transcript, respectively tion. To test this possibility we used the recently described inhibitor of p38/RK, SB203580 . Anisomycin-mediated T1 mRNA accumulation was blocked by SB203580 in a dose dependent manner and to completion at a concentration of 100mM ( Figure 6 ). Run on transcription assays showed that the inhibitor SB203580 blocked anisomycin triggered T1 gene induction (data not shown). Initially SB203580 was described as a speci®c inhibitor of p38/RK. However, it was later reported that this substance can also inhibit most of the JNK isoforms at high, and the two isoformes JNKb1 and JNKb2 even at low concentrations (Whitmarsh et al., 1997) . If anisomycin treatment led to T1 gene induction via the stimulation of these JNK isoforms we expect to observe T1 mRNA accumulation in response to u.v. irradiation. To test this possibility we subjected a NIH3T3 derived cell line which harbours a u.v. responsive TRE-CAT reporter gene to u.v. treatment. RNA was collected at dierent times following the irradiation and subjected to Northern blot analysis (Figure 7a ). No increase in accumulated T1 mRNA was observed at all time points examined and in response to three dierent doses of irradiation. As a control for the u.v. response we monitored the activation of the CAT reporter gene. CAT activity was induced following u.v. irradiation in a dose and time dependent manner (Figure 7b ). u.v. treatment, in contrast to anisomycin treatment resulted in only very weak phosphorylation of p38/RK in the studied cell line as revealed from Western blot analysis using an antibody which selectively recognizes phosphorylated p38/RK (data not shown). These results suggest that anisomycin mediated T1 gene expression is not the consequence of JNK but rather of p38/RK activation.
Anisomycin leads to p38/RK activation
To further substantiate the ®nding that anisomycin triggers p38/RK activation we investigated whether p38/RK becomes phosphorylated in response to anisomycin treatment. NIH3T3 cells were serum starved for 24 h and exposed to either emetin, cycloheximide, anisomycin or serum. Only cycloheximide and anisomycin led to p38/RK phosphorylation as revealed by Western blot analysis using an antibody which selectively recognizes the phosphorylated form of p38/RK (Figure 8a) . A parallel Western blot was reacted with an anti p38/RK antibody which does not discriminate between the phosphorylated and the unphosphorylated form to demonstrate that equal amounts of p38/RK are present in all extracts ( Figure  8b ). In several ras transformed ®broblasts the MAP kinases ERK-1 and ERK-2 were found to be permanently phosphorylated (Leevers and Marshall, 1992; Minden et al., 1994) . We investigated whether the Ras oncoprotein aects p38/RK similarly. The basal level of phosphorylated p38/RK in ras transformed NFR-2 cells was low, comparable to that in normal NIH3T3 cells. Anisomycin treatment resulted in the rapid and strong phosphorylation of p38/RK (Figure  8a,b) . Thus, ras transformation does not in¯uence basal and anisomycin mediated p38/RK phosphorylation.
One of the targets of p38/RK is MAP kinase activated protein kinase-2 (MAPKAPK-2) which upon activation phosphorylates the small heat shock protein Hsp25 (Freshney et al., 1994; Rouse et al., 1994; Cuenda et al., 1995) . Hence, anisomycin treatment should lead to Hsp25 phosphorylation. There are two major phosphorylation sites on murine Hsp25. Unphosphorylated, mono-and diphosphorylated Hsp25 have distinct migration properties on 2 D gels and give rise to the spots a, b, and c, respectively as indicated in Figure 8c . The p38/RK inhibitor SB203580 blocked T1 gene induction by anisomycin. Growth arrested NIH3T3 cells were pretreated with the indicated concentrations of SB203580 for 15 min prior to the addition of 1 mg/ml anisomycin. 6 h later total RNA was prepared and subjected to Northern blot analysis with a T1-speci®c probe (top). The same blot was reprobed with a GAPDH-speci®c probe to control for equal loading and the integrity of the RNA (bottom) . After irradiation, the cells were allowed to recover for the time periods indicated. In parallel, NIH3T3 cells were treated with 1 mg/ml anisomycin for 6 h. (a) Total RNA was harvested and subjected to Northern blot analysis using a T1 speci®c probe. (b) Protein extracts were prepared and CAT activity measured in lysates normalized for protein content ras oncogene effects on T1 gene expression NB Laursen et al al., 1993). Several stress conditions such as hyperthermia result in both, Hsp25 synthesis and phosphorylation which make it dicult to test anisomycin-mediated Hsp25 phosphorylation in these cells. We therefore chose to use the myoblast cell line C2C12 which contains high amounts of Hsp25 under normal conditions. Anisomycin treatment led to the rapid and transient phosphorylation of Hsp25 as revealed from the substantial increase in the abundance of spot c in Figure 8c . The extent of phosphorylation is similar to that seen after a heat shock (CreÃ te and Landry, 1990). This is consistent with the notion that anisomycin leads to the activation of the p38/RK-MAPKAPK-2-Hsp25 cascade.
T1 gene expression is induced in response to IL-1 and TNFa
Two well studied physiological activators of the p38/ RK signalling cascade are the proin¯ammatory cytokines IL-1 and TNFa (Freshney et al., 1994; Geng et al., 1996; Modur et al., 1996; Nahas et al., 1996; Beyaert et al., 1996) . Since ®broblasts express receptors for both ligands we expected to observe T1 gene induction in IL-1 and TNFa stimulated NIH3T3 cells. Indeed, IL-1 and TNFa treatment led to T1 mRNA accumulation in NIH3T3 cells with similar kinetics as was observed following serum stimulation (Figure 9 ). Likewise, T1 mRNA accumulated in response to IL-1 and TNFa in the ras transformed NFR-2 cell line. These cells do not express the T1 gene in response to the stimulation with serum ( Figures 1c, 9a) -Ani 60 min.
-Ani 15 min. RNA was harvested and subjected to Northern blot analysis using a T1 speci®c probe p38/RK activation is insucient to induce the T1 gene in Swiss 3T3 cells
As shown previously, treatment of Swiss 3T3 cells with cycloheximide did not result in T1 mRNA accumulation at all concentrations tested and anisomycin had only a very weak inducing eect (Figure 1c) . Since we have shown that p38/RK activation is required for anisomycin-mediated T1 gene induction we tested whether either the amount of p38/RK or its phosphorylation state in response to anisomycin diers between NIH3T3 and Swiss 3T3 cells. As shown in Figure 10 , both the total amount of p38/ RK as well as the extent of its phosphorylation after anisomycin addition are comparable in the two cell lines as revealed by Western blot analysis. Anisomycin treatment also led to the accumulation of c-fos mRNA in NIH3T3 cells (Figure 11a ). Similar amounts of c-fos mRNA were found if cells were treated with low concentrations of anisomycin (30 ng/ ml) which hardly inhibited translation and at a high concentration (1 mg/ml) which blocked translation eciently (Figure 11a ). Hence, we assume that c-fos mRNA accumulation in NIH3T3 cells is the consequence of transcriptional induction as has been shown previously in C3H 10T1/2 cells (Mahadevan and Edwards, 1991) . Following anisomycin addition, Swiss 3T3 cells accumulated c-fos mRNA to levels which even exceeded those in NIH3T3 cells. Again, this eect was similar if cells were treated with low or high concentrations of anisomycin and is therefore probably due to transcriptional stimulation. The anisomysin mediated c-fos mRNA synthesis could be inhibited with SB203580, indicating that p38/RK is involved in the induction. (Figure 11a, lane 10) . This experiment revealed that Swiss 3T3 cells are not refractory to anisomycin mediated gene induction and that anisomycin stimulated activation of the c-fos gene apparently needs an additional signal which is weak in NIH3T3 and strong in Swiss 3T3 cells.
We have shown above that T1 mRNA accumulates to a similar extent in NIH3T3 and NFR-2 cells in response to anisomycin stimulation (Figure 1c ). In contrast, anisomycin mediated c-fos mRNA accumulation is severly repressed in NFR-2 cells. (Figure 11b ). This is reminescent of serum stimulated T1 gene induction which is only observed in normal but not in ras transformed ®broblasts. These results indicate that anisomycin mediated induction of the T1 and the c-fos genes operate through dierent mechanisms.
Discussion
This study was carried out to clarify an apparent contradiction in the classi®cation of T1 as an immediate early or delayed early mitogen responsive gene. It has led us to the ®nding that the T1 gene can be induced through two dierent signal transduction cascades, the ERK and the p38/RK pathways. The stimulation of the ERK pathway by mitogens such as serum, LPA and PDGF leads to the phosphorylation of transcription factors which are involved in the stimulation of immediate early genes (Moolenaar, 1994; Hill and Treisman, 1995) . We have previously shown that T1 gene expression in response to serum and Swiss 3T3 were incubated with anisomycin at concentrations which blocked translation only partially (30 and 100 ng/ml) or completely (1 mg/ml). A Northern blot was prepared with total RNA isolated before and 1 h after anisomycin treatment and hybridized with a c-fos speci®c probe. In a separate experiment Swiss 3T3 cells were treated with the p38/RK inhibitor SB 203580 (+) or not (7) prior to the stimulation with 1 mg/ml anisomycin for 1 h. All RNA samples except those in lanes 9 and 10 were analysed on the same Northern blot. The ethidium bromide stained gels are shown as a control for equal loading of RNA. (b) NIH3T3, NFR-2, and Swiss 3T3 cells were treated with 100 ng/ml anisomycin for the time periods indicated below the lanes. RNA was prepared and analysed on the same Northern blot which was developed with a c-fos speci®c DNA probe stimulation requires the transcription factor c-Fos . c-Fos levels are very low in quiescent cells but increase drastically and transiently during the early phase of cell cycle entry (Lau and Nathans, 1991) . If the synthesis of cFos is blocked, no T1 gene induction ensues which categorizes T1 as a delayed early gene (Figure 12 ). This classi®cation holds true despite the ®nding that cycloheximide treatment of NIH3T3 cells does not preclude T1 gene expression in response to mitogenic stimulation because we have shown that puromycin and emetine which inhibit translation without stimulating signal transduction cascades block serum mediated T1 gene expression in all three ®broblastic cell lines studied. We provided evidence that the second signalling pathway which results in T1 gene expression is the p38/RK cascade. Pretreatment of cells with low concentrations of SB203580 causes the inhibition of p38/RK and certain JNK isoforms (Whitmarsh et al., 1997) and prevented anisomycin mediated T1 gene expression. Since u.v. irradiation did not result in T1 gene activation and did not cause substantial phosphorylation of p38/RK we conclude that anisomycin acts through the activation of the p38/RK pathway to stimulate T1 gene activation. This is in accordance with the observation that anisomycin stimulated T1 gene expression is not aected in ras transformed ®broblasts. ras oncogene expression results in the permanent activation of JNK and ERK but not p38/RK. Sustained activation of a signal transduction pathway should result either in the permanent stimulation of target gene expression or in gene silencing if a feedback inhibitory loop is involved.
The ability of anisomycin to stimulate the p38/RK pathway was further supported by the ®nding that anisomycin treatment resulted in the phosphorylation of p38/RK and Hsp25. The latter is a substrate of MAPKAPK-2, a downstream target of p38/RK (Freshney et al., 1994; Rouse et al., 1994; . This is in concordance with recent observations of anisomycin mediated activation of p38/RK in KB (Gould et al., 1995) and 293 cells (Brunet and PouysseÂ gur, 1996) .
Anisomycin caused T1 gene induction over a wide range of concentrations. The highest concentrations used in this study inhibited protein synthesis eciently. The transcription factors mediating T1 gene induction under these conditions must have been present before the onset of the stimulation with anisomycin. By this criterion T1 has to be classi®ed as a immediate early gene, not requiring de novo synthesis of the transcriptional stimulators. This is unlike the mechanism operating in response to growth factor mediated T1 gene induction. Mitogenic stimulation leads to the synthesis of immediate early gene products which are involved in T1 gene activation.
Anisomycin can probably cause the accumulation of speci®c mRNAs through dierent mechanisms. By virtue of its activity as a stimulator of signal transduction cascades it can cause the direct transcriptional activation of some genes such as the T1 gene. By virtue of its ability to inhibit translation it might cause the loss of labile transcriptional repressors or RNases and thereby induce transcription in an indirect manner or cause mRNA stabilization, respectively. The accumulation of tissue factor mRNA might be the result of such a mechanism as it is only observed under conditions of complete protein synthesis inhibition. T1 is one of the few genes for which transcriptional induction in response to the activation of the p38/RK pathway has been demonstrated. Such genes are the true targets of the p38/RK signal transduction cascade and the study of the mechanisms of their transcriptional induction should lead to the identi®cation of the transcription factors which are the nuclear targets of this signalling pathway.
We have observed that the c-fos gene is induced during the onset of ras oncogene expression but that it is silenced upon the prolonged presence of oncogenic p21 ras . There is evidence that this is the consequence of sustained fra-1 gene expression and the activation of cJun through its N-terminal phosphorylation by JNK. The Fra-1/c-Jun heterodimeric AP-1 complex which predominates in ras transformed NIH3T3 cells and which is present in high amounts throughout the cell cycle is an ecient repressor of the c-fos gene (manuscript submitted). The lack of c-fos gene Figure 12 Model for the induction of the T1 gene in response to mitogenic stimulation and anisomycin, IL-1, and TNFa treatment in normal NIH3T3 and ras transformed NFR-2 cells. In normal NIH3T3 ®broblasts the T1 gene can be induced through the stimulation of the p38/RK and the ERK pathway, the former being an immediate early and the latter a delayed early eect, as de®ned by the requirement for ongoing protein synthesis. In the ras transformed NFR-2 cells c-fos gene induction is blocked and consequently no T1 gene expression in response to mitogenic stimulation is observed. However, p38/RK mediated T1 gene activation is not aected in these cells induction in ras transformed cells is the likely cause for the unresponsiveness of the T1 gene to mitogen mediated activation in these cells. However, as we have shown here, T1 gene induction occurs in response to anisomycin, IL-1, and TNFa in normal and ras transformed NIH3T3 cells alike (Figure 12 ). This is a further indication that dierent transcription factors mediate the activation of the T1 gene in response to the stimulation of the p38/RK and ERK1/ERK2 pathways and in particular that c-Fos is only involved in the latter response.
The extent of anisomycin mediated gene induction varies strongly among dierent murine ®broblastic cell lines. While the T1 gene is induced with high, intermediate, and low eciency in NIH3T3, Balb/c 3T3, and Swiss 3T3 cells, respectively, the inverse is true for the c-fos gene. The presence of dierent amounts of p38/RK in these cell lines or its dierential susceptibility to phosphorylation in response to anisomycin could be excluded as possible explanations. We assume that dierent downstream target molecules of the p38/RK pathway are involved in the activation of the T1 and the c-fos gene and that these molecules are present in dierent amounts in the tested cell lines. Alternatively, other transcription factors which cooperate with the p38/RK target molecules in gene activation might be the limiting components and accumulate to dierent levels in the studied cell lines. Currently only two in vivo substrates of p38/RK are known, the related MAPKAP kinase-2 and MAPKAP kinase-3 (Ludwig et al., 1996; McLaughlin et al., 1996) . Their only known substrate is the small heat shock protein Hsp25, an unlikely candidate for gene activation. The MAPKAP kinase-3 is a target of stress and mitogen stimulated MAP kinase pathways. It is interesting to note that its activation is transient in response to mitogenic stimulation and sustained in response to stress (Ludwig et al., 1996) . Similarly, the T1 gene is induced for only a short time following cell cycle entry of quiescent cells, but its expression is prolonged in the presence of anisomycin. These kinetic considerations make the substrates of MAPKAP kinase-3 appear as good candidates for T1 gene stimulators. We have shown in this report that a T1 gene construct can be induced by anisomycin treatment in NIH3T3 cells. Promoter dissection studies should lead us to the identi®cation of the crucial DNA sequence motives involved in anisomycin mediated T1 gene activation. The transcription factors interacting with such sequence motives are expected to be the critical targets of the p38/RK signal transduction pathway. Thus, the T1 gene is a very useful tool to investigate the p38/RK pathway.
It is interesting to note that the stimulation of a hybrid protein consisting of the extracellular domain from the IL-1 receptor and the intracellular domain of T1 leads to the activation of the p38/RK pathway (Kumar et al., 1995) . We speculate that the activation of the membrane anchored form of T1 may result in enhanced T1 gene induction. An autoregulatory inhibition or stimulation of the T1 response might ensue, depending of whether the synthesis of the secreted or the membranous form of T1 occurs.
The membrane anchored form of T1 is predominantly found on the surface of mast cells. These cells store TNFa in cytoplasmatic granules. Upon antigenic stimulation they release TNFa and start to produce several cytokines including IL-1. Secreted TNFa and IL-1 might stimulate T1 gene expression in neighbouring cells resulting in the synthesis and secretion of the soluble T1 protein. Assuming that the soluble form of T1 can bind the putative T1 ligand with similar anity as the membranous form this could lead to the quenching of the T1 response. The recently described putative T1 ligand will be a useful tool to study this model.
Materials and methods

Cell cultures
The murine ®broblastic cell lines NIH3T3, Swiss 3T3, Balb/c 3T3 (clone A31), the Ha-ras (EJ) transfected clone NFR-2 , and the myoblast cell line C2C12, were grown in Dulbecco's modi®ed Eagle's medium (DMEM) (Life Technologies Inc.) supplemented with 10% fetal calf serum (FCS), penicillin (100 units/ml) and streptomycin (100 mg/ml). Cell proliferation was arrested by reducing the FCS concentration to 0.5% for 24 h. Recombinant mouse IL-1b and TNFa were purchased from Genzyme Diagnostics (Cambridge, MA) and Sigma, respectively, and used at 20 ng/ml.
To measure the inhibitory eect of anisomycin, NFR-2 cells were incubated with anisomycin which was dissolved in 50% ethanol or with the solvent only for 30 min. Thereafter, cells were metabolically labelled with 35 S-methionine for 1 h, extensively washed, lysed in a hypotonic buer (10 mM TrisHCl, pH 8.0, 0.1 mM DTT, 1 mM PMSF) and proteins were precipitated with trichloroacetic acid (TCA). The protein pellet was dissolved in the sample buer for SDS polyacrylamide gels and aliquots were spotted onto two nitro-cellulose ®lters. One ®lter was stained with amido black and protein concentrations were determined according to Schaner and Weissman (Schaner and Weissman, 1973) . The other ®lter was used to measure radioactivity. The amount of incorporated radioactivity was normalised for equal amount of protein.
u.v. irradiation
For u.v. irradiation of cells the medium was removed and the cells were irradiated in a Stratalinker 1800 u.v. Crosslinker (Stratagene) with a wavelength of 254 nm. After irradiation the medium was added back and the cells were allowed to recover for the indicated time periods.
RNA preparation and Northen blots
RNA was prepared according to Chomczynski and Sacchi (1987) and Northern blots prepared with 5 mg of total RNA per lane. The following random primed, a-32 P-dCTP labelled DNA probes were used: T1, two EcoRI-fragments (1 and 1.6 kb) from the plasmid pT1.10, spanning the entire T1 cDNA ; GAPDH, a 0.8 kb EcoRI fragment of the chicken glyceraldehyde phosphate dehydrogenase cDNA; stromelysin, a 1.8 kb EcoRI/Xhol fragment from plasmid pM124 containing cDNA of murine stromelysin (kind gift of R Friis); collagenase, a 1.5 kb Xbal fragment from the plasmid pCllase 1 (Angel et al., 1987) containing human interstial collagenase cDNA; v-fos, a 1 kb PstI fragment from the plasmid pfos-1 (Curran et al., 1982) ; mouse tissue factor, two EcoRI fragments of 711 bp and 1.07 kb (kind gift of D Nathans); CAT, the 1.25 kb EcoRI/HindII fragment of the CAT gene in the plasmid pBLCAT2 (Tsonis et al., 1988) .
Nuclear run-on transcription
Approximately 6610 7 cells were washed twice with phosphate-buered-saline (PBS) and scraped into PBS. The cells were pelleted and resuspended in HB buer (15 mM HEPES, pH 7.5; 60 mM KCl; 15 mM NaCl; 2 mM EDTA; 14.4 mM b-mercaptoethanol; 0.5 mM spermidine; 0.5 mM spermine; 10.3% w/v sucrose) supplemented with 0.5% NP-40. The nuclei were pelleted at 875 RCF for 10 min, resuspended in 10 ml HB buer, pelleted again, taken up in 15 mM HEPES (pH 7.5), 75 mM KCl, 75 mM NaCl, 0.5 mM EDTA, 1.25 mM PMSF, 0.85 mM DTT, 60% glycerol and frozen in liquid nitrogen as aliquots of 2610 7 nuclei. All procedures were performed at 0 ± 48C. The nuclei were stored at 7808C. 2610 7 nuclei were incubated at 308C for 45 min in 90 mM HEPES (pH 8.0), 160 mM KCl, 30 mM NaCl, 15 mM DTT, 2 mM MgCl2, 1.4 mM ATP, 1.4 mM CTP, 1.4 mM GTP, 150 mCi [a-32 P]UTP (3000 Ci/mmol, Amersham), 0.2 mM EDTA, 0.5 mM PMSF, 0.4 mM b-mercaptoethanol, 14.2 mM creatine phosphate, 0.1 mg/ml creatine phosphokinase, 0.6 units RNase inhibitor and 25% glycerol. The RNA was extracted by the acid guanidinium thiocyanate-phenolchloroform method (Chomczynski and Sacchi, 1987) and pelleted. The pellet was dissolved in water and puri®ed using the RNeasy system from Qiagen. The RNA was dissolved in formamide at 658C and hybridised to a Southern blot for 17 h at 488C in 50% formamide, 26SSC (0.3 M NaCl, 34.2 mM Na citrate, pH 7.0), 56Denhardt's, 1% SDS, 10 mM Tris-HCl (pH 7.5) and 100 mg/ml denatured carrier DNA. Southern blots were prepared with the following plasmid DNAs: pT1.10 (T1 cDNA) cut with EcoRI ; pT1.28 which contains a 7.6 kb EcoRI fragment from genomic T1 DNA spanning the region between 76.4 kb and +1.2 kb . Restriction with EcoRI and PstI gives rise to a 1.2 kb fragment from the transcribed region and three fragments of 0.8 kb, 2.3 kb and 3.1 kb, from the untranscribed region. After restriction digestion the DNA fragments were size fractionated on a 1% agarose gel, denatured and transferred to a nylon membrane (GeneScreen Plus).
Western blots
Cells were lysed in sample buer for SDS polyacrylamide gels, protein concentrations determined as described by Schaner and Weissmann (Schaner and Weissman, 1973) and 25 mg protein fractionated on 12.5% SDS polyacrylamide gels. For 2-dimensional gel analysis according to O'Farrell et al. (1977) the cells were lysed in sample buer A (O'Farrell, 1975) and 30 mg protein was used for the analysis. The primary antibodies used were directed against p38/RK phosphorylated at tyr 182, against total p38/RK (New England Biolabs) or against mouse Hsp25 . The secondary antibody was anti-rabbit immunoglobulin G coupled to alkaline phosphatase (Promega). Immunocomplexes were visualised enzymatically according to the manufacturer's protocol.
Plasmid construction
The plasmid pFH6 was constructed in the following way: A 5 kb SacI fragment containing part of exon 8 and 3.8 kb of the T1 gene 3'¯anking region was cloned by blunt end ligation into the SmaI site of pBC SK -(Stratagene). The coding region of the CAT gene was PCR ampli®ed from the plasmid pBLCAT2 (Tsonis et al., 1988) using the primers 5'-GGGGGCGAGATTTTCAGGAGCTAAGG-3' and 5'-GCACCAGGCGTTTAAGGGCA-3' and was cloned as a 731 bp fragment into the SmaI site upstream of the 3' T1 gene region. A 7 kb EcoRI fragment from the plasmid pSH4.9, spanning 6.2 kb of 5' T1 gene¯anking sequence, the ®rst exon and intron and part of the second exon was inserted into the EcoRI site upstream of the CAT fragment. This plasmid was cotransfected with pSV2neo into NIH3T3 cells and transfected clones were selected in medium containing G418.
Note added in proof TNFa and IL-1 mediated accumulation of T1 mRNA has recently also been reported by Kumar et al. (Kumar S, Tzimas MN, Griswold DE and Young PR (1997) . Biochem. Biophys. Res. Comm., 235, 474 ± 478.
